CytoDyn Inc.
OTC: CYDY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jacob Lalezari
- Employees
- 9
- Headquarters
- Vancouver, United States
- IPO year
- 2006
- Market cap
- $340.2M
- Website
- https://www.cytodyn.com
Loading CYDY…
Loading profile data…Frequently asked questions about CYDY
What does CytoDyn Inc. (CYDY) do?
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored f...
Where does CYDY trade?
CytoDyn Inc. (CYDY) trades on the Other OTC.
What sector is CYDY in?
CytoDyn Inc. (CYDY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CytoDyn Inc.?
Jacob Lalezari is the chief executive officer of CytoDyn Inc. (CYDY).
Where is CytoDyn Inc. headquartered?
CytoDyn Inc. is headquartered in United States.
Does CYDY pay a dividend?
CytoDyn Inc. (CYDY) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CYDY go public?
CytoDyn Inc. (CYDY) completed its initial public offering in 2006.